Search
Spotlight
In-person and virtual events just for HCPs
In-person and virtual events just for HCPs
Specialty
View More
Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer
Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer
News
OncClub
All Oncology News
OncClub
All Oncology News
Media
Insights
MedNews Week
OncChats
OncLive News Network®
OncLive TV
Peer Exchange
Podcasts
Rapid Readouts
The Talk
Insights
MedNews Week
OncChats
OncLive News Network®
OncLive TV
Peer Exchange
Podcasts
Rapid Readouts
The Talk
Conferences
Conference Coverage
Conference Listing
Conference Coverage
Conference Listing
Events
Giants of Cancer Care
CME/CE
Scientific Interchanges
State of the Science Summit / IPC
National Fellows Forum
Webinars
Giants of Cancer Care
CME/CE
Scientific Interchanges
State of the Science Summit / IPC
National Fellows Forum
Webinars
Partners
Publications
Oncology Live®
Oncology Fellows
Supplements and Featured Publications
All Publications
Oncology Live®
Oncology Fellows
Supplements and Featured Publications
All Publications
Resources
Interactive Tools
Sponsored
Biomarker Consortium
Interactive Tools
Sponsored
Biomarker Consortium
Subscribe
Search
Spotlight
In-person and virtual events just for HCPs
Specialty
See All >
Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer
Matthew Powell, MD, Washington University School of Medicine
home
Articles
Upcoming Clinical Trials for Ovarian Cancer
July 20th 2020
Emerging Therapies in Recurrent Ovarian Cancer
July 20th 2020
Antibody Drug Conjugates for Ovarian Cancer
July 20th 2020
Neoadjuvant Therapy Versus Surgery for Ovarian Cancer
July 20th 2020
New Data for Secondary Surgery in Ovarian Cancer
July 20th 2020
PARP Inhibitors in Recurrent Ovarian Cancer
July 20th 2020
Expert Approaches for Treating Recurrent Ovarian Cancer
July 20th 2020
Emerging Combinations in the Frontline Setting of Ovarian Cancer
July 20th 2020
Patient Preference for Treatment in Ovarian Cancer
July 20th 2020
PAOLA-1 Study Surgical Subset for Ovarian Cancer
July 20th 2020
NCCN Guidelines and FDA Approvals for Treating Ovarian Cancer
July 20th 2020
Personalized Dosing of Niraparib in Ovarian Cancer
July 20th 2020
Treating Homologous Recombination Proficient Ovarian Cancer
July 20th 2020
Treating BRCA+ Ovarian Cancer
July 20th 2020
Need for Frontline Comparison Trials in Ovarian Cancer
July 20th 2020
Impact of HRD Status on Frontline Treatment of Ovarian Cancer
July 20th 2020
The Impact of PAOLA-1 on Frontline Treatment of Ovarian Cancer
July 20th 2020
Biomarker-Driven Frontline Ovarian Cancer Treatment
July 20th 2020
An Introduction to the Discussion of Ovarian Cancer
July 20th 2020